menu

Talking Through the Therapeutic Landscape of IgAN

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Talking Through the Therapeutic Landscape of IgAN

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    IgA nephropathy has a few aspects to it that make it challenging to develop medications, particularly, focused medications. So what are the challenges or limitations associated with the therapies? Join Dr. Charles Turck as he discusses this in-depth with Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Irving Medical Center.

     

    Dr. Canetta did not receive compensation for this interview.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    IgA nephropathy has a few aspects to it that make it challenging to develop medications, particularly, focused medications. So what are the challenges or limitations associated with the therapies? Join Dr. Charles Turck as he discusses this in-depth with Dr. Pietro Canetta, Associate Professor of Medicine at Columbia University Irving Medical Center.

     

    Dr. Canetta did not receive compensation for this interview.

Facebook Comments

Schedule23 Apr 2024